Immune-mediated neuropathies in myeloma patients treated with bortezomib

Clinical Neurophysiology

Volumn 119, Issue 11, 2008, Pages 2507-2512

  Ravaglia, Sabrina ^a   Corso, Alessandro ^a   Piccolo, Giovanni ^a   Lozza, Alessandro ^a   Alfonsi, Enrico ^a   Mangiacavalli, Silvia ^a   Varettoni, Marzia ^a   Zappasodi, Patrizia ^a   Moglia, Arrigo ^a   Lazzarino, Mario ^a   Costa, Alfredo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Bortezomib; IVIg; Multiple myeloma; Peripheral neuropathy; Polyradiculoneuritis

Indexed keywords

ALBUMIN; BORTEZOMIB; BUPRENORPHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FENTANYL; GABAPENTIN; IMMUNOGLOBULIN; MELPHALAN; PREDNISONE; PREGABALIN; STEROID; THALIDOMIDE; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BURNING SENSATION; CANCER RADIOTHERAPY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; CYTODIAGNOSIS; CYTOLOGY; DEMYELINATION; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; ELECTROPHYSIOLOGY; FEMALE; HEART FUNCTION TEST; HUMAN; HYPOREFLEXIA; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INFLAMMATION; LOW DRUG DOSE; LUMBAR SPINE; LUNG INFECTION; MALE; MOTOR DYSFUNCTION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE ACTION POTENTIAL; MUSCLE WEAKNESS; NERVE CONDUCTION; NERVE POTENTIAL; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PARESTHESIA; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PRIORITY JOURNAL; SENSORY DYSFUNCTION; SENSORY STIMULATION; SIDE EFFECT; SPINAL CORD; TENDON REFLEX; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACTION POTENTIALS; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEURAL CONDUCTION; POLYNEUROPATHIES; PYRAZINES; REACTION TIME;

EID: 54149104958     PISSN: 13882457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinph.2008.08.007     Document Type: Article

References (20)

1. Calhoun E.A., Welshman E.E., Chang C.H., Lurain J.R., Fishman D.A., Hunt T.L., et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13 6 (2003) 741-748
2. Cavaletti G., Gilardini A., Canta A., Rigamonti L., Rodriguez-Menendez V., Ceresa C., et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 204 1 (2007) 317-325
3. Cornblath D.R., Chaudhry V., Carter K., Lee D., Seysedadr M., Miernicki M., et al. Total neuropathy score: validation and reliability study. Neurology 53 8 (1999) 1660-1664
4. Cornblath D.R. Electrophysiology in Guillain-Barre syndrome. Ann Neurol 27 Suppl. (1990) S17-S20
5. Hideshima T., Richardson P.J., Palombella V.J., Elliott P.J., Adams J., and Anderson K.C. The proteasome inhibitor PS-341 inhibits growth, induced apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61 7 (2001) 3071-3076
6. Jagannath S., Barlogie B., Berenson J., Siegel D., Irwin D., Richardson P.G., et al. A phase 2 study of two doses of Bortezomib in relapsed or refractory myeloma. Br J Haematol 127 (2004) 165-172
7. Jagannath S., Durie B., Wolf J., Camacho E., Irwin D., Lutzky J., et al. Bortezomib therapy alone and in combination with dexamethasone for patients with previously untreated multiple myeloma. Blood (ASH Annual Meeting Abstracts) 106 (2005) 786
8. Ma C., Mandrekar S.J., Alberts S.R., Croghan G.A., Jatoi A., Reid J.M., et al. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chemother Pharmacol 59 2 (2007) 207-215
9. Nencioni A., Grunebach F., Patrone F., Ballestrero A., and Brossart P. The proteasome and its inhibitors in immune regulation and immune disorders. Crit Rev Immunol 26 6 (2006) 487-498
10. Peters G., and Larner A.J. Chronic inflammatory demyelinating polyneuropathy after autologous peripheral blood stem cell transplantation. J Peripher Nerv Syst 10 4 (2005) 384-385
11. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. A phase 2 study of Bortezomib in relapsed, refractory myeloma. N Engl J Med 348 (2003) 2609-2617
12. Richardson P.G., Briemberg H., Jagannath S., Wen P.Y., Barlogie B., Berenson J., et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24 19 (2006) 3113-3120
13. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., et al. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 (2005) 2487-2498
14. Richez C., Blanco P., Lagueny A., Schaeverbeke T., and Dehais J. Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers. Neurology 64 8 (2005) 1468-1470 Apr 26
15. Shin I.S., Baer A.N., Kwon H.J., Papadopoulos E.J., and Siegel J.N. Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum 54 5 (2006) 1429-1434 May
16. Stubblefield M.D., Slovin S., MacGregor-Cortelli B., Muzzy J., Scher H., Wright J., et al. An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib. Clin Oncol (R Coll Radiol) 18 5 (2006) 410-418
17. Stubgen J.P. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 37 3 (2008) 281-292
18. Terenghi F., Ardolino G., and Nobile-Orazio E. Guillain-Barré syndrome after combined CHOP and rituximab therapy in non-Hodgkin lymphoma. J Peripher Nerv Syst 12 2 (2007) 142-143
19. Thompson E.J. The CSF proteins: A biochemical approach (1988), Elsevier, Amsterdam
20. Zappasodi P. Bortezomib-combination based therapy in relapsed-refractory myeloma patients. Haematologica 2 5 (2006) 5-7